Bioequivalence Study of Tacrolimus 5 mg Capsule Under Fasting Condition
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to demonstrate bioequivalence between Test Product (A):
Tacrolimus Capsules 5 mg, manufactured by Panacea Biotec Limited, India and the corresponding
Reference Product (B): Prograf (Tacrolimus) Capsules 5 mg, manufactured by Astellas Pharma,
Inc., USA in 36 normal, healthy, adult, male subjects under fasting condition.